Ajanta Pharma Ltd
Ajanta Pharma Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Ajanta Pharma Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY 2027 Revenue from Operations: Rs. 1,794 Cr.
As stated in Ajanta Pharma Ltd's Q2 FY27 results statement · published 30 Oct 2026. Reported figures, not investment advice.
Based on Ajanta Pharma Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Q2 FY 2027 Revenue from Operations: Rs. Q2 FY 2027 figures vs Q2 FY 2026: • Revenue from operations: Rs.
From Ajanta Pharma Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
Revenue & Sales Performance
- Q2 FY 2027 Revenue from Operations: Rs. 1,794 Cr (Page 49)
- Q2 FY 2026 Revenue from Operations: Rs. 1,354 Cr
- Year-on-year Growth: 33% (Page 49)
- Q2 FY 2027 Consolidated Sales: Rs. 1,782 Cr (Page 47)
- Q2 FY 2026 Consolidated Sales: Rs. 1,339 Cr
- Year-on-year Growth: 33% (Page 47)
- Branded Generics Sales Q2 FY 2027: Rs. 1,182 Cr, up from Rs. 963 Cr in Q2 FY 2026 (23% growth) (Page 47)
2 more points from Ajanta Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ajanta Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure on property, plant and equipment & intangible assets (including capital advances) for 6 months ended 30 Sept 2026 was Rs. 622.57 crore (Standalone) and Rs. 749.52 crore (Consolidated).
- Proceeds from sale of property, plant and equipment are minimal (Rs. 0.42 crore Standalone; Rs. 0.42 crore Consolidated).
- Emphasis on "New product launches across markets" and "Gain market share in existing products" as part of strategic priorities.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ajanta Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Ajanta Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Ajanta Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹388 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ajanta Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ajanta Pharma Ltd Q2 FY27 results?
Q2 FY 2027 Revenue from Operations: Rs. Q2 FY 2027 figures vs Q2 FY 2026: • Revenue from operations: Rs.
What is Ajanta Pharma Ltd share price analysis?
Ajanta Pharma Ltd currently shows a neutral. The stock trades at a P/E of 38.6 with a market cap of ₹43,846 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma Ltd planning capital expenditure?
Capital expenditure on property, plant and equipment & intangible assets (including capital advances) for 6 months ended 30 Sept 2026 was Rs.
Keep Ajanta Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.